CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.18 – $1.30
Volume7,377
Market cap$8M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.21M
Price / earnings
—
Price / book
1.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.56×
Profitability
Earnings per share
-$2.19
Return on assets
-105.71%
Return on equity
-357.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.63×
Current ratio
4.96×
Quick ratio
4.96×
Cash ratio
1.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CALC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.43M
$1.91M
$2.13M
$1.28M
$1.77M
$2.57M
$2.27M
$2.34M
Research and development
$2.32M
$2.1M
$3.49M
$3.11M
$3.85M
$4.05M
$4.22M
$3.83M
Total operating expenses
$4.75M
$4.01M
$5.61M
$4.39M
$5.62M
$6.62M
$6.5M
$6.17M
Operating income
-$4.75M
-$4.01M
-$5.61M
-$4.39M
-$5.62M
-$6.62M
-$6.5M
-$6.17M
Interest expense
-$357K
-$325K
-$319K
-$325K
-$326K
-$324K
-$447K
$0
Income before taxes
-$1.67M
-$7.65M
$4.87M
-$10.91M
-$7.8M
-$5.96M
-$5.24M
-$4.47M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.67M
-$7.65M
$4.87M
-$10.91M
-$7.8M
-$5.96M
-$5.24M
-$4.47M
Net income attributable to common shareholders
-$1.67M
-$7.65M
$4.98M
-$10.76M
-$7.8M
-$5.96M
-$5.04M
-$4.26M
EBITDA
-$4.74M
-$4.01M
-$5.6M
-$4.38M
-$5.61M
-$6.61M
-$6.48M
-$6.16M
Basic earnings per share
-$0.24
-$2.25
$1.55
-$3.39
-$2.59
-$2.00
-$1.80
-$1.64
Diluted earnings per share
-$0.24
-$2.25
$1.50
-$3.39
-$2.59
-$2.00
-$1.80
-$1.68
Recent news
Company coverage with links to the original publishers.
CalciMedica Inc. (CALC) received an upgrade to Zacks Rank #2 (Buy) driven by upward revisions in earnings estimates. The company's consensus estimate has increased 63.2% over the past three months, positioning it in the top 20% of Zacks-covered stocks. The upgrade reflects improved earnings outlook that could translate into buying pressure and stock price appreciation in the near term.
Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.
The Dow Jones index closed lower by around 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
CalciMedica
The Trade: CalciMedica, Inc. (NASDAQ: CALC) Chief Business Officer Eric W Roberts acquired a total of 4,000 shares an average price of $3.90. To acquire these shares, it cost around $15,600.
What’s Happening: On March 28, CalciMedica posted a fourth-quarter loss of 23 cents ...
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here’s the latest list of major overbought players in this sector.
PepGen Inc. (NASDAQ: PEPG)
On Jan. 8, PepGen said First Patient was dosed in CONNECT1-EDO51 Phase 2 clinical trial of PGN-EDO51 for duchenne muscular dystrophy patients amenable to Exon 51 skipping. The company’s stock ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.